Positive Results for Human Genome’s Lupus Drug Benlysta
Biotechnology company Human Genome Sciences reported that its drug candidate Benlysta reduced symptoms of lupus in a long-term clinical trial.
feature2
NeuroSearch’s Tesofensine Advances to Phase III Testing
Yesterday, OneMedPlace reported on several companies that are developing anti-obesity drugs. Another name can be added to the list.
VIVUS’ Qnexa Shows Promise For Diabetics
VIVUS, a pharmaceutical company specializing in products to treat sexual function, announced that their experimental obesity drug Qnexa was shown to improve blood sugar control in patients with type 2 diabetes.
Correction: Sentinel – Symphony Medical
In last week’s Sentinel, OneMedPlace reported that Symphony Medical had initiated a Phase II clinical trial of their Plexisyl-AF device to treat atrial fibrillation.
HealthTronics to Buy Endocare
HealthTronics announced that it has entered into a definitive merger agreement with Endocare.
Companies Rush to Create Swine Flu Vaccines
With flu season approaching, the U.S. federal government has earmarked nearly $1 billion for the development of swine flu vaccines.
Electro-Optical Submits MelaFind for Premarket Approval
Electro-Optical Sciences anounced that it has submitted a Premarket Approval Application to the U.S. Food and Drug Administration for MelaFind.
Medtronic Acquires Diabetes Tech from PreciSense
Medtronic announced at its annual investor meeting that it has acquired substantially all glucose monitoring technology from Danish company PreciSense.
VIVUS Initiates Safety Study for Erectile Dysfunction Drug
Pharmaceutical company VIVUS has initiated an open label safety study of the investigational drug avanafil in males with erectile dysfunction.
Transcend Medical Raises $20 Million for Glaucoma Device
VentureWire reports that Transcend Medical, a developer of devices to treat glaucoma, has raised $20 million in equity.